Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology (2024). The use of preimplantation genetic testing for aneuploidy: a committee opinion. Fertil Steril. https://doi.org/10.1016/j.fertnstert.2024.04.013
Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. The use of preimplantation genetic testing for aneuploidy: a committee opinion. Fertil Steril. 2024. doi:10.1016/j.fertnstert.2024.04.013
Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. "The use of preimplantation genetic testing for aneuploidy: a committee opinion." Fertil Steril, 2024.
For EndNote, Zotero or Mendeley:
Open access
Free to read
No reuse license
Free to read at the publisher (reported by Unpaywall and OpenAlex, not verified by RRM Academy)
RRM Academy Synopsis
Committee finds routine PGT-A has no demonstrated benefit
A 2024 committee opinion from two reproductive medicine societies finds that PGT-A has not been shown to help IVF patients as a routine screen. Randomized trials in women with available blastocysts found similar overall pregnancy outcomes after frozen embryo transfer, with or without the test.
Key Findings
The committee reports that PGT-A, as a routine screen for people having IVF, has no demonstrated value.
Some older studies from single centers linked PGT-A to more live births among patients with a good outlook.
Recent multicenter randomized trials in women with available blastocysts found similar overall pregnancy outcomes after frozen embryo transfer, with or without PGT-A.
The committee calls the benefit of PGT-A for lowering clinical miscarriage unclear and says the trials have important limitations.
The opinion replaces the 2018 document of the same name.
Interpretation
The record available here is the published abstract of a committee opinion, so the detail of the full document is not summarized. A committee opinion is a consensus position built from reviewing trials, and it reports no new data of its own. The trials it cites enrolled women who already had blastocysts, so the conclusions cover that group. The committee describes its own cited evidence on miscarriage as limited.
RRM Context
RRM looks for the cause of infertility first. PGT-A screens embryos that IVF has already created and does not look for that cause.
Our editorial summary of this paper, not the article's abstract.
Abstract
The use of preimplantation genetic testing for aneuploidy (PGT-A) in the United States has been increasing steadily. Moreover, the underlying technology used for 24-chromosome analysis continues to evolve rapidly. The value of PGT-A as a routine screening test for all patients undergoing in vitro fertilization has not been demonstrated. Although some earlier single-center studies reported higher live-birth rates after PGT-A in favorable-prognosis patients, recent multicenter, randomized control trials in women with available blastocysts concluded that the overall pregnancy outcomes via frozen embryo transfer were similar between PGT-A and conventional in vitro fertilization. The value of PGT-A to lower the risk of clinical miscarriage is also unclear, although these studies have important limitations. This document replaces the document of the same name, last published in 2018.
Clinical Guidelines and Standards › Guidelines by Clinical Area › Fertility and Infertility Guidelines · Assisted Reproduction › Add-Ons and Adjuncts › Preimplantation Genetic Testing
PMID 38762806 38762806 DOI 10.1016/j.fertnstert.2024.04.013 10.1016/j.fertnstert.2024.04.013 Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology et al. 2024, Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology 2024
